Newsroom

Sorted by: Latest
-

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details a...
-

AM Best Affirms Credit Ratings of The Hand-in-Hand Mutual Fire Insurance Company Limited and Hand-in-Hand Mutual Life Assurance Company Limited

MEXICO CITY--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating (FSR) of B++ (Good) and the Long-Term Issuer Credit Rating (Long-Term ICR) of “bbb+” (Good) of The Hand-in-Hand Mutual Fire Insurance Company Limited (HIHF) (Guyana). The outlook of the FSR is stable while the outlook of the Long-Term ICR is negative. Concurrently, AM Best has affirmed the FSR of B++ (Good) and the Long-Term ICR of “bbb” (Good) of Hand-in-Hand Mutual Life Assurance Company Limited (HIHL) (Guyana). T...
-

AM Best Afirma Calificaciones Crediticias de The Hand-in-Hand Mutual Fire Insurance Company Limited y Hand-in-Hand Mutual Life Assurance Company Limited

México, Ciudad de México--(BUSINESS WIRE)--AM Best ha afirmado la Calificación de Fortaleza Financiera (FSR, por sus siglas en inglés) de B++ (Buena) y la Calificación Crediticia de Emisor de Largo Plazo (ICR, por sus siglas en inglés) de “bbb+” (Buena) de Hand-in-Hand Mutual Fire Insurance Company Limited (HIHF) (Guyana). La perspectiva de la FSR es estable, mientras que la perspectiva de la ICR de Largo Plazo es negativa. Al mismo tiempo, AM Best ha afirmado la FSR de B++ (Buena) y la ICR de L...
-

PennyMac Financial Services, Inc. Reschedules Third Quarter 2026 Earnings Call to 5:30 PM ET on Thursday, October 29

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--PennyMac Financial Services, Inc. (NYSE: PFSI) will announce results for the quarter ended September 30, 2026, in a news release to be issued after the market close on Thursday, October 29, 2026. The conference call and live audio webcast is being rescheduled to 5:30 pm. Eastern Time from the originally scheduled 5:00 p.m. Eastern Time. The release, webcast, and accompanying materials will be available online at pfsi.pennymac.com. A replay of the webca...
-

NextGen Healthcare Appoints Anthony Palladino as Chief Financial Officer

DETROIT--(BUSINESS WIRE)--NextGen Healthcare, a leading provider of innovative, cloud-based healthcare technology solutions, today announced Anthony Palladino as Chief Financial Officer. Palladino joins NextGen Healthcare from Thoma Bravo, where he served as an operating partner, working alongside portfolio company leadership teams to strengthen financial operations, improve operating efficiency and accelerate profitable growth across the firm’s software portfolio. Prior to Thoma Bravo, Palladi...
-

Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Roche announced today late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimized standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P<0.0001), relative to placebo at 37 wee...
-

Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today late-breaking oral presentation data from the ongoing Phase III IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimized standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P<0.0001), relat...
-

Macy’s, Inc. Board of Directors Declares Quarterly Dividend

NEW YORK--(BUSINESS WIRE)--Macy’s, Inc. Board of Directors Declares Quarterly Dividend...
-

The Capital Corporation Advises Champion Coach Inc. on Its Partnership With Hoffmann Family of Companies

GREENVILLE, S.C.--(BUSINESS WIRE)--The Capital Corporation served as the exclusive investment banking advisor to Champion Coach in its partnership with Hoffmann Family of Companies....
-

The Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement Scheme

HOUSTON--(BUSINESS WIRE)--Building on decades of holding pharmaceutical companies responsible for dangerous products and unlawful business practices, The Lanier Law Firm played a pivotal role supporting Texas Attorney General Ken Paxton in securing a $45 million settlement with Gilead Sciences, Inc. Announced on Oct. 22, the settlement resolves claims that the company offered illegal incentives to medical providers to prescribe its drugs over competitors’ medications. In many cases, these presc...